PSG.DE PharmaSGP SE XETRA bounces from oversold lows 16 Feb 2026: EUR 30 test

We see an intraday rebound in PSG.DE stock after a short oversold run, with the share trading at €29.00 on XETRA on 16 Feb 2026. Volume is elevated at 12,424 shares versus an average of 5,399, a 2.30x relative volume signal that buyers stepped in around the day low of €28.60. The bounce aligns with a technical recovery attempt toward the near-term resistance at €30.00, while fundamentals show a modest PE near 17.26 and positive margins. We view this move as an oversold-bounce trade, not a trend reversal, and outline targets, risk points, and Meyka AI model forecasts below.

Intraday price action for PSG.DE stock

PSG.DE stock opened at €28.80, hit a day low of €28.60 and rebounded to €29.00 on XETRA during intraday trading in Germany. Volume of 12,424.00 shares is roughly 2.30 times the average, showing a real-time shift in supply-demand at these levels. The immediate technical read is a short-term oversold bounce into the €29.00–€30.00 resistance zone; traders should watch whether intraday follow-through lifts price above €30.00.

Fundamentals and valuation of PSG.DE stock

PharmaSGP Holding SE reports EPS of €1.68 and a trailing PE of 17.26, with market cap approximately €333862500.00 on XETRA. Key ratios show price/book 9.12, price/sales 3.55, and a free cash flow yield near 6.52%, reflecting healthy cash generation versus valuation multiple. The company operates in Healthcare (Drug Manufacturers – Specialty & Generic) with net profit margin 16.59% and low leverage (debt/equity 0.02), which supports the thesis that this bounce rests on solid near-term fundamentals.

Technical setup and oversold-bounce strategy for PSG.DE stock

The technical picture for PSG.DE stock shows a confluence: 50-day average €28.52 and 200-day average €26.10, putting current price near short-term support. Relative volume spike and intraday rejection at the low point are classic oversold-bounce signals for a tactical trade with tight stops. We recommend a setup where the stop is below €28.00 and a first profit target at €30.00, with a secondary target near €33.00 if momentum confirms.

Meyka AI grade and PSG.DE stock forecast

Meyka AI rates PSG.DE with a score of 78.90 out of 100 — Grade B+ with suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year price of €27.36, a 3-year price of €29.48, and a 5-year price of €31.56, where the 1-year figure implies a -5.66% move from the current €29.00 price. Forecasts are model-based projections and not guarantees.

Risks, catalysts and sector context for PSG.DE stock

Primary risks for PSG.DE stock include working capital cycles (days inventory on hand 400.36) and concentrated OTC distribution channels in Europe. Catalysts include wider distribution wins, margin expansion, or a positive sales update in export markets like Italy and France. Sector comparatives show the Healthcare group trading at higher average PE (~29.26); PharmaSGP’s lower leverage and solid margins give upside if growth accelerates, but inventory intensity and valuation multiples deserve monitoring.

Final Thoughts

Key takeaways for PSG.DE stock: intraday action on 16 Feb 2026 shows an oversold bounce into €29.00, with elevated volume confirming buyer interest. Short-term trade setup: stop below €28.00, initial target €30.00, extended target €33.00 if breakout follows. Meyka AI’s forecast model projects a 1-year price of €27.36 (implied -5.66% vs current price €29.00), a 3-year price of €29.48 (implied +1.66%), and a 5-year price of €31.56 (implied +8.83%). These model outputs suggest the intraday bounce can be used for a tactical oversold trade but that longer-term gains rely on improved sales and inventory efficiency. We link the company IR page for updates and our platform page for live metrics: PharmaSGP website and Boerse Frankfurt PSG.DE quote. Meyka AI, an AI-powered market analysis platform, provides real-time signals and grades but forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.